ALK B — Alk-Abello A/S Share News
0.000.00%
Last trade - 00:00- DKK51.65bn
- DKK50.34bn
- DKK6.31bn
Brief: Alk Gets Positive Recommendation For Eurneffy 1 Mg Nasal Spray
Brief: ALK-Abello Says ATP Reduces Ownership In ALK To Below 5%
Outlook hike, Q3 beat boost Alk-Abello shares
Brief: ALK-Abello Q3 EBIT DKK 423 Million
Brief: ALK-Abello Outlook FY EBIT Margin 26%
TD Cowen raises Alaska Air's PT, sees recovery despite fuel, IT headwinds
Brief: ALK And Gensci Partner To Expand The AIT Market In China
ALK-Abello shares shine on Q2 sales, investment details
Brief: Alk-Abello Q2 Tablet Sales Grew By 16% To DKK 831 Mln
Brief: ALK-Abello Q2 Free Cash Flow DKK 216 Million
Brief: ALK-Abello Upgrades Its FY Revenue Outlook
Brief: National Institute For Health And Care Excellence Recommended Use Of Tree Pollen Tablet Itulazax For Treatment In Adults
Brief: Alk-Abello A/S : Tree Pollen Tablet (Itulazax) Now Recommended By Nice For Use In UK Health System
Brief: Alk-Abello's Eurneffy Treatment Approved In UK
Brief: UK's MHRA Approves EURneffy To Be Used For Emergency Treatment Of Serious Allergic Reactions
Brief: ALK-Abello Says Itulatek Approved For Treatment Of Children And Adolescents In Canada
ALK-Abello shares shine after Q1 earnings beat
Brief: Alk-Abello Q1 EBIT Up At DKK 469 Mln
Promotion Agreement In U.S.